NMUS 19M O/S, 5M float, $500,000 non-dilutive financing confirmed. Buy this dip, easy mover, prime acquisition candidate in the $8 Billion industry for the treatment of Glaucoma.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.